Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Humira in Chinese Crohn's Disease Patients (Post-marketing Safety and Effectiveness)
CTR20220996Phase 4Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of adalimumab in Crohn's disease, sponsored by AbbVie Inc.. Started Apr 2022; status: completed.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on CTR20220996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220996.